---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045964"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:31:56.530018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS

## Summary
- Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.
- Cash $81.9M at Sep 30, 2024; subsequent $58.1M warrant exercise proceeds extend runway into at least 2027.
- First patient dosed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa; topline data expected 2026.
- R&D expenses $9.5M, up from $1.2M YoY due to AVTX-009 trial initiation and development costs.
- Total revenues minimal at $249K; operating loss $12.9M for the quarter.

## SEC filing metadata
- accession: 0001628280-24-045964
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/0001628280-24-045964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024045964/avtx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045964
- JSON: https://secwatch.observer/filing/0001628280-24-045964.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.